| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Disease Transmission, Infectious | 22 | 2021 | 9044 | 2.42 | Why? |
| Immunogenicity, Vaccine | 12 | 2021 | 4624 | 2.23 | Why? |
| Editorial Policies | 4 | 2020 | 408 | 2.21 | Why? |
| Immunization Programs | 7 | 2021 | 2006 | 2.18 | Why? |
| Antibodies, Monoclonal | 12 | 2021 | 8041 | 2.01 | Why? |
| Viral Vaccines | 12 | 2020 | 7560 | 1.97 | Why? |
| Immunization, Secondary | 5 | 2021 | 1649 | 1.78 | Why? |
| Public Health Practice | 6 | 2021 | 945 | 1.77 | Why? |
| Mycobacterium tuberculosis | 12 | 2019 | 1164 | 1.68 | Why? |
| Cell Division | 3 | 2019 | 136 | 1.62 | Why? |
| Dexamethasone | 7 | 2021 | 2055 | 1.23 | Why? |
| Clinical Trials as Topic | 13 | 2021 | 7330 | 1.20 | Why? |
| Coronavirus Infections | 43 | 2020 | 253789 | 1.20 | Why? |
| Information Dissemination | 5 | 2021 | 2986 | 1.17 | Why? |
| Pneumonia, Viral | 42 | 2020 | 243684 | 1.17 | Why? |
| Mycobacterium smegmatis | 4 | 2019 | 27 | 1.12 | Why? |
| International Cooperation | 4 | 2021 | 3436 | 1.06 | Why? |
| Periodicals as Topic | 4 | 2020 | 1492 | 1.04 | Why? |
| Betacoronavirus | 39 | 2020 | 204454 | 0.99 | Why? |
| Receptors, Interleukin-6 | 2 | 2021 | 1383 | 0.98 | Why? |
| Tuberculosis | 8 | 2021 | 2895 | 0.97 | Why? |
| Mycobacterium | 3 | 2019 | 143 | 0.97 | Why? |
| Communicable Disease Control | 12 | 2021 | 29620 | 0.97 | Why? |
| Patient Acuity | 7 | 2021 | 1755 | 0.92 | Why? |
| Epoprostenol | 1 | 2021 | 41 | 0.90 | Why? |
| Antiviral Agents | 12 | 2021 | 41703 | 0.87 | Why? |
| Antitubercular Agents | 7 | 2019 | 775 | 0.85 | Why? |
| Immunologic Factors | 3 | 2021 | 4206 | 0.84 | Why? |
| Government Employees | 1 | 2020 | 45 | 0.84 | Why? |
| Patient Care | 3 | 2020 | 1664 | 0.83 | Why? |
| Controlled Clinical Trials as Topic | 1 | 2020 | 53 | 0.82 | Why? |
| Immunization, Passive | 9 | 2021 | 10067 | 0.81 | Why? |
| Adenovirus Vaccines | 1 | 2021 | 103 | 0.81 | Why? |
| Anti-Inflammatory Agents | 5 | 2021 | 6153 | 0.80 | Why? |
| Minority Groups | 2 | 2021 | 1631 | 0.80 | Why? |
| Clinical Laboratory Techniques | 7 | 2020 | 23402 | 0.78 | Why? |
| Genetic Vectors | 6 | 2021 | 1600 | 0.78 | Why? |
| Cell Wall | 5 | 2019 | 62 | 0.78 | Why? |
| Attitude to Health | 3 | 2021 | 2002 | 0.77 | Why? |
| Pandemics | 45 | 2021 | 389249 | 0.76 | Why? |
| Immunoglobulins, Intravenous | 2 | 2021 | 2705 | 0.75 | Why? |
| Mandatory Reporting | 1 | 2020 | 140 | 0.75 | Why? |
| Biomedical Research | 5 | 2021 | 5270 | 0.74 | Why? |
| Injections, Intramuscular | 1 | 2021 | 800 | 0.73 | Why? |
| Ethionamide | 1 | 2017 | 5 | 0.71 | Why? |
| Glucocorticoids | 4 | 2021 | 4431 | 0.71 | Why? |
| Immunity, Mucosal | 1 | 2021 | 426 | 0.70 | Why? |
| Spiro Compounds | 1 | 2017 | 28 | 0.69 | Why? |
| Oxygen | 3 | 2021 | 3715 | 0.69 | Why? |
| Immunocompromised Host | 4 | 2021 | 5150 | 0.68 | Why? |
| Federal Government | 2 | 2020 | 562 | 0.68 | Why? |
| Extensively Drug-Resistant Tuberculosis | 1 | 2018 | 87 | 0.68 | Why? |
| Isoxazoles | 1 | 2017 | 68 | 0.67 | Why? |
| Intersectoral Collaboration | 2 | 2021 | 1065 | 0.67 | Why? |
| Antibiotics, Antitubercular | 1 | 2017 | 65 | 0.67 | Why? |
| Cell Polarity | 1 | 2017 | 85 | 0.67 | Why? |
| Adenosine Monophosphate | 5 | 2021 | 5652 | 0.66 | Why? |
| Alanine | 5 | 2021 | 5687 | 0.66 | Why? |
| Research Support as Topic | 1 | 2021 | 327 | 0.66 | Why? |
| Animal Experimentation | 1 | 2018 | 120 | 0.66 | Why? |
| Humans | 91 | 2021 | 930598 | 0.64 | Why? |
| State Government | 1 | 2021 | 416 | 0.62 | Why? |
| Mass Vaccination | 3 | 2021 | 1101 | 0.62 | Why? |
| Drug Evaluation | 3 | 2020 | 100 | 0.62 | Why? |
| United States | 19 | 2021 | 46150 | 0.60 | Why? |
| Thrombosis | 4 | 2021 | 7504 | 0.60 | Why? |
| Vaccine Potency | 3 | 2021 | 339 | 0.60 | Why? |
| Repressor Proteins | 1 | 2017 | 232 | 0.59 | Why? |
| Bacterial Proteins | 5 | 2019 | 1318 | 0.59 | Why? |
| Mass Media | 2 | 2021 | 837 | 0.59 | Why? |
| Hydroxychloroquine | 6 | 2020 | 12447 | 0.58 | Why? |
| Purines | 1 | 2020 | 816 | 0.56 | Why? |
| Faculty, Medical | 1 | 2021 | 595 | 0.56 | Why? |
| Antibodies, Monoclonal, Humanized | 3 | 2021 | 9335 | 0.56 | Why? |
| Prodrugs | 1 | 2017 | 264 | 0.56 | Why? |
| Adenoviridae | 4 | 2021 | 1151 | 0.56 | Why? |
| Goals | 1 | 2018 | 335 | 0.56 | Why? |
| Azetidines | 1 | 2020 | 722 | 0.55 | Why? |
| Drug Approval | 2 | 2020 | 1325 | 0.54 | Why? |
| Drug Discovery | 4 | 2021 | 3092 | 0.54 | Why? |
| Microbial Sensitivity Tests | 4 | 2019 | 2886 | 0.54 | Why? |
| In Vitro Techniques | 3 | 2021 | 1027 | 0.51 | Why? |
| Global Health | 10 | 2021 | 13911 | 0.51 | Why? |
| World Health Organization | 3 | 2020 | 4213 | 0.50 | Why? |
| Health Planning | 1 | 2020 | 607 | 0.48 | Why? |
| Genetic Variation | 3 | 2021 | 3919 | 0.48 | Why? |
| Contact Tracing | 3 | 2020 | 8448 | 0.46 | Why? |
| Sulfonamides | 1 | 2020 | 1294 | 0.46 | Why? |
| Acute Lung Injury | 1 | 2020 | 904 | 0.46 | Why? |
| Hypertension, Pulmonary | 1 | 2021 | 970 | 0.45 | Why? |
| Research Personnel | 1 | 2021 | 1037 | 0.43 | Why? |
| Politics | 2 | 2021 | 1824 | 0.43 | Why? |
| Antibodies, Neutralizing | 10 | 2021 | 25288 | 0.42 | Why? |
| Commerce | 1 | 2020 | 1109 | 0.42 | Why? |
| Evolution, Molecular | 2 | 2021 | 3691 | 0.42 | Why? |
| Systemic Inflammatory Response Syndrome | 2 | 2021 | 6653 | 0.41 | Why? |
| Pyrazoles | 1 | 2020 | 1791 | 0.40 | Why? |
| Masks | 3 | 2021 | 8528 | 0.40 | Why? |
| Health Resources | 2 | 2021 | 2592 | 0.40 | Why? |
| Treatment Outcome | 12 | 2021 | 51732 | 0.40 | Why? |
| Health Education | 4 | 2021 | 1539 | 0.39 | Why? |
| Rifampin | 3 | 2018 | 276 | 0.39 | Why? |
| Piperidines | 3 | 2021 | 795 | 0.39 | Why? |
| Health Care Rationing | 2 | 2021 | 2558 | 0.39 | Why? |
| Vulnerable Populations | 2 | 2020 | 3099 | 0.38 | Why? |
| United States Food and Drug Administration | 3 | 2021 | 1276 | 0.38 | Why? |
| Communication | 3 | 2021 | 5206 | 0.38 | Why? |
| Transcription, Genetic | 2 | 2017 | 1326 | 0.38 | Why? |
| Healthcare Disparities | 3 | 2021 | 3893 | 0.38 | Why? |
| Observational Studies as Topic | 3 | 2021 | 1887 | 0.37 | Why? |
| Antihypertensive Agents | 1 | 2021 | 1962 | 0.37 | Why? |
| Health Services Accessibility | 6 | 2021 | 10697 | 0.37 | Why? |
| Vaccination Refusal | 3 | 2021 | 831 | 0.36 | Why? |
| Vaccines, Synthetic | 1 | 2021 | 3231 | 0.36 | Why? |
| Anti-Infective Agents | 1 | 2020 | 1766 | 0.36 | Why? |
| Adaptive Immunity | 1 | 2020 | 2585 | 0.35 | Why? |
| Ritonavir | 2 | 2020 | 4212 | 0.35 | Why? |
| Antibodies, Viral | 10 | 2021 | 51949 | 0.35 | Why? |
| Asymptomatic Diseases | 4 | 2021 | 3444 | 0.35 | Why? |
| Drug Resistance, Bacterial | 4 | 2018 | 1414 | 0.35 | Why? |
| Placebos | 2 | 2021 | 629 | 0.34 | Why? |
| Thrombocytopenia | 4 | 2021 | 2093 | 0.34 | Why? |
| Public Policy | 1 | 2020 | 1894 | 0.34 | Why? |
| Virus Replication | 7 | 2021 | 14331 | 0.34 | Why? |
| Leadership | 1 | 2021 | 2241 | 0.33 | Why? |
| Time Factors | 8 | 2021 | 31397 | 0.33 | Why? |
| Education, Medical, Graduate | 1 | 2021 | 2082 | 0.32 | Why? |
| Immunotherapy | 1 | 2020 | 2421 | 0.32 | Why? |
| Single-Cell Analysis | 1 | 2017 | 2450 | 0.32 | Why? |
| South Africa | 3 | 2021 | 3326 | 0.32 | Why? |
| Infusions, Intravenous | 2 | 2021 | 1224 | 0.32 | Why? |
| Gene Deletion | 2 | 2019 | 430 | 0.31 | Why? |
| Nursing Homes | 2 | 2021 | 4155 | 0.31 | Why? |
| Latent Tuberculosis | 1 | 2010 | 324 | 0.31 | Why? |
| Adrenal Cortex Hormones | 2 | 2020 | 6537 | 0.31 | Why? |
| Trust | 3 | 2021 | 1487 | 0.31 | Why? |
| Phenotype | 1 | 2017 | 4037 | 0.30 | Why? |
| Viral Load | 6 | 2021 | 15850 | 0.30 | Why? |
| Chemoprevention | 2 | 2020 | 585 | 0.30 | Why? |
| Genetic Predisposition to Disease | 1 | 2020 | 4027 | 0.29 | Why? |
| Sensitivity and Specificity | 3 | 2021 | 22971 | 0.29 | Why? |
| Janus Kinase Inhibitors | 2 | 2021 | 682 | 0.29 | Why? |
| Health Equity | 3 | 2021 | 1223 | 0.29 | Why? |
| Vaccines, Attenuated | 2 | 2020 | 952 | 0.29 | Why? |
| Drug Therapy, Combination | 4 | 2021 | 7268 | 0.28 | Why? |
| Pregnancy | 3 | 2021 | 23879 | 0.27 | Why? |
| Mutation | 3 | 2021 | 12376 | 0.27 | Why? |
| Disaster Planning | 3 | 2021 | 1680 | 0.27 | Why? |
| Time-to-Treatment | 4 | 2021 | 5883 | 0.27 | Why? |
| Vaccines, Inactivated | 2 | 2021 | 1562 | 0.26 | Why? |
| Disease Eradication | 2 | 2021 | 581 | 0.25 | Why? |
| Drug Administration Schedule | 2 | 2020 | 2324 | 0.25 | Why? |
| Social Isolation | 2 | 2021 | 5932 | 0.25 | Why? |
| Pyrimidines | 2 | 2021 | 1557 | 0.25 | Why? |
| Oxygen Inhalation Therapy | 3 | 2021 | 3629 | 0.25 | Why? |
| Drug Industry | 2 | 2021 | 689 | 0.25 | Why? |
| Prisoners | 2 | 2021 | 738 | 0.24 | Why? |
| Public Health Administration | 2 | 2021 | 846 | 0.24 | Why? |
| Specimen Handling | 1 | 2020 | 6190 | 0.24 | Why? |
| Mycolic Acids | 2 | 2019 | 6 | 0.24 | Why? |
| Peptidoglycan | 2 | 2018 | 27 | 0.24 | Why? |
| Asthma | 1 | 2021 | 4383 | 0.23 | Why? |
| RNA, Messenger | 3 | 2020 | 5131 | 0.23 | Why? |
| Anti-Bacterial Agents | 3 | 2019 | 10083 | 0.23 | Why? |
| Bahamas | 1 | 2021 | 6 | 0.23 | Why? |
| Spike Glycoprotein, Coronavirus | 6 | 2021 | 37182 | 0.23 | Why? |
| Patient Acceptance of Health Care | 1 | 2020 | 5002 | 0.23 | Why? |
| Molecular Diagnostic Techniques | 1 | 2018 | 4239 | 0.22 | Why? |
| Inflammation | 2 | 2021 | 13255 | 0.22 | Why? |
| Vaccination Coverage | 2 | 2021 | 1249 | 0.22 | Why? |
| Lopinavir | 3 | 2020 | 4308 | 0.22 | Why? |
| Disease Reservoirs | 2 | 2021 | 1672 | 0.22 | Why? |
| Vaccination | 6 | 2021 | 19050 | 0.22 | Why? |
| Hospitalization | 3 | 2021 | 54280 | 0.22 | Why? |
| Gene Expression | 2 | 2017 | 3332 | 0.22 | Why? |
| Infection Control | 5 | 2021 | 23131 | 0.22 | Why? |
| Personal Protective Equipment | 3 | 2020 | 15978 | 0.22 | Why? |
| Interferon-gamma | 1 | 2011 | 2711 | 0.21 | Why? |
| Randomized Controlled Trials as Topic | 4 | 2020 | 10649 | 0.21 | Why? |
| Serology | 1 | 2020 | 60 | 0.21 | Why? |
| Virginia | 1 | 2021 | 228 | 0.21 | Why? |
| Epidemics | 1 | 2021 | 6407 | 0.21 | Why? |
| Antacids | 1 | 2019 | 12 | 0.21 | Why? |
| Mass Screening | 1 | 2020 | 8005 | 0.21 | Why? |
| Oligosaccharides | 1 | 2020 | 69 | 0.21 | Why? |
| Mycobacterium bovis | 2 | 2019 | 125 | 0.20 | Why? |
| Plasma | 2 | 2020 | 1809 | 0.20 | Why? |
| Phagosomes | 1 | 2019 | 32 | 0.20 | Why? |
| History, 18th Century | 1 | 2020 | 192 | 0.20 | Why? |
| Journalism, Medical | 1 | 2020 | 50 | 0.20 | Why? |
| Tuberculosis, Pulmonary | 1 | 2010 | 1171 | 0.20 | Why? |
| Cell Cycle Proteins | 2 | 2019 | 297 | 0.20 | Why? |
| Azabicyclo Compounds | 1 | 2021 | 91 | 0.20 | Why? |
| Quinazolines | 1 | 2021 | 126 | 0.20 | Why? |
| Microbial Viability | 3 | 2019 | 406 | 0.20 | Why? |
| Respiratory Insufficiency | 1 | 2021 | 7301 | 0.20 | Why? |
| Clinical Studies as Topic | 1 | 2020 | 118 | 0.20 | Why? |
| Iceland | 1 | 2020 | 314 | 0.20 | Why? |
| Antigens, Surface | 1 | 2020 | 181 | 0.20 | Why? |
| Interinstitutional Relations | 1 | 2021 | 170 | 0.20 | Why? |
| Research Design | 3 | 2021 | 5830 | 0.19 | Why? |
| Bacillus subtilis | 1 | 2019 | 34 | 0.19 | Why? |
| Tongue | 1 | 2020 | 132 | 0.19 | Why? |
| Fluorescence | 2 | 2018 | 475 | 0.19 | Why? |
| Carrier State | 2 | 2021 | 2100 | 0.19 | Why? |
| Hydrolases | 1 | 2019 | 34 | 0.19 | Why? |
| Injections, Subcutaneous | 1 | 2021 | 647 | 0.19 | Why? |
| Dose-Response Relationship, Immunologic | 1 | 2020 | 593 | 0.19 | Why? |
| Clinical Trials, Phase I as Topic | 1 | 2020 | 242 | 0.19 | Why? |
| Gene Expression Profiling | 1 | 2010 | 3788 | 0.19 | Why? |
| Comorbidity | 2 | 2020 | 34796 | 0.19 | Why? |
| DNA Replication | 1 | 2019 | 121 | 0.19 | Why? |
| Genetic Loci | 1 | 2020 | 439 | 0.18 | Why? |
| Cross-Linking Reagents | 1 | 2018 | 91 | 0.18 | Why? |
| Aminoglycosides | 1 | 2018 | 94 | 0.18 | Why? |
| Walk Test | 1 | 2021 | 461 | 0.18 | Why? |
| Amidohydrolases | 1 | 2017 | 30 | 0.18 | Why? |
| Pyrazinamide | 1 | 2017 | 38 | 0.17 | Why? |
| Confidence Intervals | 1 | 2020 | 744 | 0.17 | Why? |
| Respiration, Artificial | 2 | 2020 | 22116 | 0.17 | Why? |
| Mycobacterium Infections | 1 | 2018 | 72 | 0.17 | Why? |
| Child Behavior | 1 | 2021 | 266 | 0.17 | Why? |
| Fluoresceins | 1 | 2017 | 46 | 0.17 | Why? |
| Disease Resistance | 1 | 2020 | 236 | 0.17 | Why? |
| Bioethical Issues | 1 | 2021 | 233 | 0.17 | Why? |
| Lactones | 1 | 2017 | 62 | 0.17 | Why? |
| Platelet Factor 4 | 1 | 2021 | 385 | 0.17 | Why? |
| Symptom Flare Up | 1 | 2021 | 432 | 0.17 | Why? |
| Public-Private Sector Partnerships | 1 | 2020 | 259 | 0.17 | Why? |
| Cyclonic Storms | 1 | 2021 | 236 | 0.17 | Why? |
| Endonucleases | 1 | 2017 | 68 | 0.16 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 9706 | 0.16 | Why? |
| Physicians, Primary Care | 1 | 2020 | 298 | 0.16 | Why? |
| HIV Protease Inhibitors | 1 | 2020 | 434 | 0.16 | Why? |
| Escherichia coli | 3 | 2019 | 1547 | 0.16 | Why? |
| Influenza Pandemic, 1918-1919 | 1 | 2021 | 339 | 0.16 | Why? |
| Authorship | 1 | 2019 | 240 | 0.16 | Why? |
| Oxidoreductases | 1 | 2017 | 136 | 0.16 | Why? |
| Benzofurans | 1 | 2017 | 91 | 0.16 | Why? |
| Professional-Patient Relations | 1 | 2021 | 426 | 0.16 | Why? |
| Anti-Asthmatic Agents | 1 | 2021 | 427 | 0.15 | Why? |
| Gene Silencing | 1 | 2017 | 213 | 0.15 | Why? |
| Gene Knockdown Techniques | 1 | 2017 | 347 | 0.15 | Why? |
| Immunoglobulins | 1 | 2021 | 811 | 0.15 | Why? |
| Equipment and Supplies | 1 | 2020 | 440 | 0.15 | Why? |
| Age Factors | 3 | 2021 | 21039 | 0.15 | Why? |
| Financing, Government | 1 | 2020 | 434 | 0.15 | Why? |
| Compassionate Use Trials | 1 | 2020 | 632 | 0.15 | Why? |
| Anticoagulants | 3 | 2021 | 9563 | 0.15 | Why? |
| Ireland | 1 | 2021 | 1456 | 0.15 | Why? |
| Mentoring | 1 | 2021 | 432 | 0.14 | Why? |
| Child | 5 | 2021 | 70012 | 0.14 | Why? |
| DNA Mutational Analysis | 1 | 2017 | 581 | 0.14 | Why? |
| Healthy Volunteers | 1 | 2020 | 1444 | 0.14 | Why? |
| Washington | 1 | 2020 | 1722 | 0.14 | Why? |
| Breath Tests | 1 | 2018 | 338 | 0.14 | Why? |
| History, 20th Century | 1 | 2021 | 1282 | 0.14 | Why? |
| Treatment Failure | 1 | 2020 | 2106 | 0.14 | Why? |
| Drug Resistance, Viral | 1 | 2021 | 1083 | 0.14 | Why? |
| Vaccines, DNA | 1 | 2020 | 871 | 0.13 | Why? |
| Protein Biosynthesis | 1 | 2018 | 653 | 0.13 | Why? |
| Community Participation | 1 | 2020 | 605 | 0.13 | Why? |
| Nose | 1 | 2020 | 1093 | 0.13 | Why? |
| Immunization Schedule | 1 | 2021 | 1305 | 0.13 | Why? |
| Population Surveillance | 2 | 2021 | 4967 | 0.13 | Why? |
| Virus Shedding | 2 | 2020 | 5834 | 0.13 | Why? |
| History, 21st Century | 1 | 2021 | 1849 | 0.13 | Why? |
| Information Seeking Behavior | 1 | 2020 | 539 | 0.13 | Why? |
| Virulence | 1 | 2021 | 2172 | 0.13 | Why? |
| Antigens, Viral | 2 | 2021 | 6298 | 0.13 | Why? |
| Standard of Care | 1 | 2020 | 1297 | 0.13 | Why? |
| Quarantine | 4 | 2021 | 18418 | 0.13 | Why? |
| Hospital Administration | 1 | 2020 | 650 | 0.13 | Why? |
| Respiratory Tract Diseases | 1 | 2021 | 1061 | 0.12 | Why? |
| Antigens, Bacterial | 2 | 2017 | 330 | 0.12 | Why? |
| Government Regulation | 1 | 2020 | 842 | 0.12 | Why? |
| Interleukin-6 | 2 | 2021 | 7522 | 0.12 | Why? |
| Animals | 8 | 2021 | 78931 | 0.12 | Why? |
| Lipids | 1 | 2019 | 1079 | 0.12 | Why? |
| Consumer Health Information | 1 | 2020 | 750 | 0.12 | Why? |
| Ships | 1 | 2020 | 1046 | 0.12 | Why? |
| Israel | 1 | 2021 | 2751 | 0.11 | Why? |
| Self Care | 1 | 2020 | 918 | 0.11 | Why? |
| Respiratory Syncytial Virus Infections | 1 | 2021 | 1234 | 0.11 | Why? |
| Africa | 1 | 2021 | 2986 | 0.11 | Why? |
| Hong Kong | 1 | 2021 | 3361 | 0.11 | Why? |
| Health Facilities | 1 | 2020 | 1230 | 0.11 | Why? |
| Sequence Analysis, RNA | 1 | 2021 | 2290 | 0.11 | Why? |
| Immunomodulation | 1 | 2020 | 1472 | 0.11 | Why? |
| Disease Outbreaks | 1 | 2020 | 27595 | 0.11 | Why? |
| ABO Blood-Group System | 1 | 2020 | 995 | 0.11 | Why? |
| Small Molecule Libraries | 1 | 2019 | 1060 | 0.11 | Why? |
| Public Opinion | 1 | 2021 | 1165 | 0.11 | Why? |
| Hypersensitivity | 1 | 2021 | 1137 | 0.11 | Why? |
| Isoniazid | 1 | 2011 | 105 | 0.11 | Why? |
| United Kingdom | 2 | 2021 | 18046 | 0.10 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 1261 | 0.10 | Why? |
| Drug Combinations | 1 | 2020 | 3852 | 0.10 | Why? |
| Lung Diseases, Interstitial | 1 | 2021 | 1476 | 0.10 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 1454 | 0.10 | Why? |
| Autoantibodies | 1 | 2021 | 2094 | 0.10 | Why? |
| Drug Resistance, Multiple, Bacterial | 1 | 2018 | 1115 | 0.10 | Why? |
| Immunity | 1 | 2021 | 2651 | 0.10 | Why? |
| Practice Guidelines as Topic | 3 | 2020 | 15421 | 0.10 | Why? |
| Virus Latency | 1 | 2011 | 251 | 0.09 | Why? |
| Social Media | 2 | 2021 | 5798 | 0.09 | Why? |
| Skin | 1 | 2021 | 2096 | 0.09 | Why? |
| Drug Evaluation, Preclinical | 1 | 2020 | 3347 | 0.09 | Why? |
| Resource Allocation | 1 | 2020 | 1771 | 0.09 | Why? |
| Flow Cytometry | 1 | 2017 | 2393 | 0.09 | Why? |
| Epidemiological Monitoring | 1 | 2021 | 3493 | 0.09 | Why? |
| Guidelines as Topic | 1 | 2021 | 2844 | 0.09 | Why? |
| CRISPR-Cas Systems | 1 | 2017 | 1397 | 0.09 | Why? |
| Public Health Surveillance | 1 | 2021 | 3129 | 0.09 | Why? |
| Immunity, Cellular | 1 | 2020 | 3614 | 0.08 | Why? |
| Point-of-Care Testing | 1 | 2020 | 2782 | 0.08 | Why? |
| Risk Factors | 3 | 2021 | 71621 | 0.08 | Why? |
| SARS Virus | 2 | 2021 | 13021 | 0.08 | Why? |
| Whole Genome Sequencing | 1 | 2018 | 3239 | 0.08 | Why? |
| Risk Assessment | 2 | 2021 | 25439 | 0.08 | Why? |
| Japan | 1 | 2020 | 6653 | 0.08 | Why? |
| Adolescent | 3 | 2021 | 86841 | 0.08 | Why? |
| Patient Selection | 1 | 2021 | 4560 | 0.08 | Why? |
| Nucleic Acid Amplification Techniques | 1 | 2020 | 3388 | 0.08 | Why? |
| New York City | 1 | 2020 | 7432 | 0.08 | Why? |
| Mice | 4 | 2019 | 21357 | 0.08 | Why? |
| Serologic Tests | 1 | 2020 | 4359 | 0.07 | Why? |
| Hypoxia | 1 | 2020 | 3626 | 0.07 | Why? |
| Drug Synergism | 2 | 2019 | 833 | 0.07 | Why? |
| Chronic Disease | 1 | 2020 | 5139 | 0.07 | Why? |
| Diagnosis, Differential | 1 | 2020 | 7220 | 0.07 | Why? |
| Predictive Value of Tests | 1 | 2020 | 9537 | 0.07 | Why? |
| Azithromycin | 1 | 2020 | 3943 | 0.07 | Why? |
| Drug Design | 1 | 2017 | 2627 | 0.07 | Why? |
| Mobile Applications | 1 | 2020 | 3032 | 0.07 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2017 | 3607 | 0.07 | Why? |
| Reproducibility of Results | 2 | 2019 | 11304 | 0.07 | Why? |
| Ambulatory Care | 1 | 2021 | 4947 | 0.07 | Why? |
| Europe | 1 | 2020 | 12702 | 0.06 | Why? |
| Sex Factors | 1 | 2021 | 11014 | 0.06 | Why? |
| India | 1 | 2021 | 11875 | 0.06 | Why? |
| Receptors, Virus | 1 | 2020 | 5659 | 0.06 | Why? |
| RNA, Viral | 2 | 2020 | 32276 | 0.06 | Why? |
| Health Behavior | 1 | 2021 | 4449 | 0.06 | Why? |
| Health Status Disparities | 1 | 2020 | 4072 | 0.06 | Why? |
| Physicians | 1 | 2021 | 4214 | 0.06 | Why? |
| Health Personnel | 2 | 2021 | 29646 | 0.05 | Why? |
| Nasopharynx | 1 | 2020 | 10224 | 0.05 | Why? |
| Adult | 4 | 2021 | 244371 | 0.05 | Why? |
| Education, Distance | 1 | 2021 | 4956 | 0.05 | Why? |
| Internship and Residency | 1 | 2021 | 4987 | 0.05 | Why? |
| Mycobacterium kansasii | 1 | 2019 | 14 | 0.05 | Why? |
| DNA Gyrase | 1 | 2019 | 30 | 0.05 | Why? |
| Topoisomerase II Inhibitors | 1 | 2019 | 36 | 0.05 | Why? |
| Aminoacyltransferases | 1 | 2018 | 10 | 0.05 | Why? |
| Aminoacylation | 1 | 2018 | 1 | 0.05 | Why? |
| Edeine | 1 | 2018 | 2 | 0.05 | Why? |
| Health Policy | 1 | 2020 | 6242 | 0.05 | Why? |
| Streptomycin | 1 | 2018 | 8 | 0.05 | Why? |
| Penicillin-Binding Proteins | 1 | 2018 | 31 | 0.05 | Why? |
| Injections, Intraperitoneal | 1 | 2018 | 69 | 0.05 | Why? |
| Bacillus | 1 | 2018 | 32 | 0.05 | Why? |
| Gene Expression Regulation, Bacterial | 1 | 2019 | 143 | 0.05 | Why? |
| RNA, Transfer | 1 | 2018 | 66 | 0.05 | Why? |
| Polyketide Synthases | 1 | 2017 | 1 | 0.05 | Why? |
| Cytokines | 1 | 2021 | 15010 | 0.05 | Why? |
| Female | 5 | 2021 | 380317 | 0.05 | Why? |
| Colony Count, Microbial | 1 | 2019 | 177 | 0.05 | Why? |
| Amoxicillin | 1 | 2018 | 98 | 0.04 | Why? |
| Acyltransferases | 1 | 2017 | 61 | 0.04 | Why? |
| Streptococcus thermophilus | 1 | 2017 | 4 | 0.04 | Why? |
| Operon | 1 | 2017 | 12 | 0.04 | Why? |
| Cell Membrane Permeability | 1 | 2017 | 84 | 0.04 | Why? |
| Interferons | 1 | 2010 | 2885 | 0.04 | Why? |
| Folic Acid | 1 | 2019 | 172 | 0.04 | Why? |
| Transcription Initiation Site | 1 | 2017 | 11 | 0.04 | Why? |
| Cross Infection | 1 | 2020 | 8675 | 0.04 | Why? |
| Gas Chromatography-Mass Spectrometry | 1 | 2018 | 187 | 0.04 | Why? |
| Tryptophan | 1 | 2019 | 218 | 0.04 | Why? |
| Substrate Specificity | 1 | 2019 | 639 | 0.04 | Why? |
| Biomarkers | 1 | 2020 | 23361 | 0.04 | Why? |
| Escherichia coli Proteins | 1 | 2018 | 168 | 0.04 | Why? |
| Genetic Techniques | 1 | 2017 | 79 | 0.04 | Why? |
| Specific Pathogen-Free Organisms | 1 | 2017 | 358 | 0.04 | Why? |
| Macrophages | 2 | 2019 | 2784 | 0.04 | Why? |
| Streptococcus pyogenes | 1 | 2017 | 118 | 0.04 | Why? |
| Critical Care | 1 | 2020 | 14081 | 0.04 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.04 | Why? |
| Lysosomes | 1 | 2019 | 416 | 0.04 | Why? |
| Hydrogen-Ion Concentration | 1 | 2019 | 993 | 0.04 | Why? |
| Principal Component Analysis | 1 | 2018 | 689 | 0.04 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2010 | 4545 | 0.04 | Why? |
| Public Health | 1 | 2021 | 16359 | 0.04 | Why? |
| HIV Infections | 1 | 2021 | 11620 | 0.04 | Why? |
| Pregnancy Complications, Infectious | 1 | 2021 | 11559 | 0.04 | Why? |
| Influenza, Human | 1 | 2020 | 10779 | 0.04 | Why? |
| Drug Resistance, Microbial | 1 | 2019 | 419 | 0.04 | Why? |
| Amino Acids | 1 | 2018 | 552 | 0.03 | Why? |
| Intensive Care Units | 1 | 2021 | 29594 | 0.03 | Why? |
| China | 1 | 2021 | 50654 | 0.03 | Why? |
| Molecular Structure | 1 | 2019 | 1539 | 0.03 | Why? |
| Organ Specificity | 1 | 2018 | 1070 | 0.03 | Why? |
| Delivery of Health Care | 1 | 2020 | 15909 | 0.03 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2010 | 5837 | 0.03 | Why? |
| Severity of Illness Index | 1 | 2021 | 48226 | 0.03 | Why? |
| T-Lymphocytes | 1 | 2010 | 6670 | 0.03 | Why? |
| Emergency Service, Hospital | 1 | 2017 | 14232 | 0.03 | Why? |
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2017 | 624 | 0.03 | Why? |
| Coronavirus | 1 | 2021 | 18339 | 0.03 | Why? |
| Male | 3 | 2021 | 367725 | 0.03 | Why? |
| Kinetics | 1 | 2018 | 3238 | 0.03 | Why? |
| Molecular Targeted Therapy | 1 | 2019 | 1579 | 0.03 | Why? |
| Bronchoalveolar Lavage Fluid | 1 | 2018 | 2309 | 0.02 | Why? |
| Membrane Proteins | 1 | 2018 | 1733 | 0.02 | Why? |
| Mice, Inbred C57BL | 1 | 2018 | 5542 | 0.02 | Why? |
| Mice, Inbred BALB C | 1 | 2017 | 5814 | 0.02 | Why? |
| Pilot Projects | 1 | 2018 | 5182 | 0.02 | Why? |
| Aged | 1 | 2020 | 215776 | 0.02 | Why? |
| Models, Molecular | 1 | 2017 | 7616 | 0.02 | Why? |
| Cell Line | 1 | 2017 | 12040 | 0.01 | Why? |
| Models, Biological | 1 | 2018 | 4907 | 0.01 | Why? |
| Neutrophils | 1 | 2018 | 5476 | 0.01 | Why? |
| Protein Binding | 1 | 2018 | 11430 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2018 | 10998 | 0.01 | Why? |
| Prevalence | 1 | 2019 | 25773 | 0.01 | Why? |